NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SGMO

Sangamo Therapeutics Inc

Jul 11 • 04:00PM ET

0.4920

Dollar change -0.0080
Percentage change -1.60	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD CRSP NTLA BMRN EDIT QURE BLUE FGEN VYGR VXRT

| Held by: VTI VXF SCHA PRFZ FESM ITOT GNOM SCHB XDNA QQQS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.38	Insider Own	3.16%	Shs Outstand	245.40M	Perf Week	-6.62%
Market Cap	120.74M	Forward P/E	-	EPS next Y	-0.34	Insider Trans	0.00%	Shs Float	237.64M	Perf Month	-4.52%
Enterprise Value	120.44M	PEG	-	EPS next Q	-0.01	Inst Own	21.44%	Short Float	10.17%	Perf Quarter	-29.58%
Income	-80.74M	P/S	1.89	EPS this Y	25.97%	Inst Trans	-14.62%	Short Ratio	4.81	Perf Half Y	-64.09%
Sales	63.76M	P/B	22.60	EPS next Y	6.79%	ROA	-75.06%	Short Interest	24.18M	Perf YTD	-51.76%
Book/sh	0.02	P/C	4.80	EPS next 5Y	24.16%	ROE	-262.12%	52W High	3.18 -84.52%	Perf Year	40.57%
Cash/sh	0.10	P/FCF	-	EPS past 3/5Y	26.70% 10.57%	ROIC	-271.09%	52W Low	0.37 32.15%	Perf 3Y	-89.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.48% -10.81%	Gross Margin	86.26%	Volatility	7.20% 8.67%	Perf 5Y	-94.99%
Dividend TTM	-	EV/Sales	1.89	EPS Y/Y TTM	79.41%	Oper. Margin	-128.52%	ATR (14)	0.04	Perf 10Y	-95.07%
Dividend Ex-Date	-	Quick Ratio	0.76	Sales Y/Y TTM	239.92%	Profit Margin	-126.63%	RSI (14)	44.04	Recom	1.83
Dividend Gr. 3/5Y	- -	Current Ratio	0.76	EPS Q/Q	48.97%	SMA20	-3.83%	Beta	1.19	Target Price	4.10
Payout	-	Debt/Eq	5.07	Sales Q/Q	1238.25%	SMA50	-8.09%	Rel Volume	0.64	Prev Close	0.50
Employees	183	LT Debt/Eq	5.07	Earnings	May 12 AMC	SMA200	-56.60%	Avg Volume	5.02M	Price	0.49
IPO	Apr 06, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	-19.35% -27.67%	Trades		Volume	3,202,137	Change	-1.60%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-24	Upgrade	Truist	Hold → Buy	$7
Dec-10-24	Reiterated	H.C. Wainwright	Buy	$10
Nov-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6 → $2
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform	$5 → $1.50
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform	$16
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $5
Jun-13-22	Resumed	Wedbush	Neutral	$5
May-04-21	Initiated	RBC Capital Mkts	Outperform	$22
Jan-07-21	Resumed	Guggenheim	Neutral	$16
Jan-06-21	Initiated	Stifel	Hold	$16
Dec-16-20	Resumed	H.C. Wainwright	Buy	$25
Sep-08-20	Initiated	BofA Securities	Buy	$20
Jul-07-20	Initiated	SunTrust	Buy	$22
Aug-26-19	Initiated	H.C. Wainwright	Buy	$16
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy	$24
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-22-17	Resumed	Jefferies	Buy	$17

Show Previous Ratings

Jul-03-25 09:18AM	H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data (Insider Monkey)
Jun-24-25 08:05AM	Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease (Business Wire) +18.94%
May-13-25 01:01PM	Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com) -38.40%
12:14PM	Q1 2025 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-12-25 06:26PM	Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results (Business Wire) +6.66%
06:23PM	Loading…
06:23PM	Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering (Business Wire)
05:55PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:53PM	Sangamo: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day (Business Wire)
May-08-25 09:15AM	Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates (Zacks) +10.67%
May-06-25 04:35PM	Sangamo Therapeutics Announces First Quarter 2025 Earnings Call (Business Wire) -15.00% +6.27%
08:30AM	Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease (Business Wire)
May-05-25 10:00AM	Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
May-01-25 10:01AM	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-28-25 04:31PM	Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire) -5.93%
02:57PM	Loading…
Apr-04-25 02:57PM	Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (Seeking Alpha) +5.50%
Apr-03-25 04:01PM	Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System (Business Wire)
Mar-18-25 09:00AM	Q4 2024 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -16.23%
03:01AM	Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-17-25 05:10PM	Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Sangamo: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Mar-06-25 04:05PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference (Business Wire) +14.30%
Feb-06-25 08:05AM	Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile (Business Wire)
Jan-07-25 11:32AM	Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025 (Insider Monkey)
Jan-02-25 07:03AM	Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership (Barrons.com) +10.78%
Dec-31-24 11:52AM	Top Stock Movers Now: Moderna, Verisign, Dave, and More (Investopedia) -56.41%
11:18AM	Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future (GuruFocus.com)
10:34AM	Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact (Investopedia)
10:23AM	SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse (Insider Monkey)
09:56AM	Loading…
09:56AM	Sangamo stock plummets 50% after Pfizer ends gene therapy deal (Yahoo Finance Video)
09:55AM	Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug (Bloomberg)
09:14AM	Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact (Benzinga)
08:30AM	Sangamos stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership (Pharmaceutical Technology)
06:38AM	Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal (Investing.com)
Dec-30-24 04:15PM	Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizers Decision to Cease Development of Giroctocogene Fitelparvovec (Business Wire) -8.59%
02:56PM	Why Is Sangamo Therapeutics Inc. (SGMO) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-20-24 04:37AM	Astellas and Sangamo sign capsid deal for neurological diseases (Pharmaceutical Technology) +6.93%
Dec-19-24 02:30AM	Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases (Business Wire)
02:30AM	Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases (PR Newswire)
Nov-19-24 04:15PM	Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain (Business Wire)
Nov-13-24 09:49AM	Q3 2024 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -9.96%
02:16AM	Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 05:15PM	Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:09PM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results (Business Wire)
Nov-04-24 04:15PM	Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast (Business Wire) -7.45% +24.14%
Oct-23-24 07:45AM	Merck acquires cancer drug startup; Elevidys ex-US sales rise (BioPharma Dive) +27.27%
Oct-22-24 08:05AM	Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 (Business Wire) +32.53%
Aug-07-24 01:24PM	Q2 2024 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.46%
04:32AM	Genentech and Sangamo to develop neurodegenerative disease therapies (Pharmaceutical Technology)
Aug-06-24 05:35PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +28.95%
04:37PM	Sangamo: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results (Business Wire)
08:11AM	Roche licenses Sangamos technology for another shot at Alzheimers drugs (BioPharma Dive)
08:05AM	Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases (Business Wire)
Jul-30-24 04:15PM	Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast (Business Wire) -23.64% +11.80%
Jul-24-24 06:55AM	Sangamo Therapeutics Reports on Pfizers Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate (Business Wire) +39.55%
May-12-24 08:28AM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 03:58PM	Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights (GuruFocus.com) +7.26%
May-09-24 08:58PM	SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:25PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:23PM	Sangamo: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results (Business Wire)
10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:05AM	Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing (Business Wire)
May-02-24 04:15PM	Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast (Business Wire) +6.48%
Apr-22-24 04:35PM	Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire)
Mar-22-24 08:05AM	Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering (Business Wire) -27.55%
Mar-14-24 07:23AM	Q4 2023 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 08:21AM	Sangamo: Q4 Earnings Snapshot (Associated Press Finance) -8.83%
08:05AM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
08:01AM	Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs (Business Wire)
Mar-12-24 06:30PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast (Business Wire)
Feb-12-24 08:05AM	Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease (Business Wire) +40.15%
Feb-05-24 06:01PM	Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile (Business Wire) +13.91% -7.02%
Nov-03-23 05:03PM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 08:15AM	Sangamo to cut jobs again with planned business overhaul (BioPharma Dive) -22.14%
Nov-01-23 07:05PM	Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update (GuruFocus.com) -6.25%
04:13PM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 10:02AM	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-25-23 04:15PM	Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast (Business Wire)
Oct-24-23 02:01AM	Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Sep-20-23 04:15PM	Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit (Business Wire)
Aug-25-23 01:38PM	Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases (InvestorPlace) -12.49%
Aug-08-23 05:30PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -7.89%
04:26PM	Sangamo: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 04:15PM	Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast (Business Wire)
Jul-20-23 08:05AM	Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing (Business Wire)
Jul-19-23 07:08AM	The past five years for Sangamo Therapeutics (NASDAQ:SGMO) investors has not been profitable (Simply Wall St.)
Jul-17-23 08:05AM	Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids (Business Wire)
Jun-29-23 08:05AM	Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease (Business Wire)
Jun-28-23 09:20AM	FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing (Zacks)
Jun-14-23 08:16AM	We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate (Simply Wall St.)
May-22-23 08:05AM	Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease (Business Wire) +5.43%
May-18-23 07:04AM	Industry Analysts Just Upgraded Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Forecasts By 52% (Simply Wall St.)
May-16-23 08:00AM	Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer (Business Wire)
May-02-23 04:30PM	Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire) -9.27%

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGMO

Sangamo Therapeutics Inc

Upgrade your FINVIZ experience